Idarucizumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Idarucizumab: From Dabigatran Anticoagulation Reversal to Hemoglobinopathy
One-Sentence Summary
Idarucizumab is a monoclonal antibody fragment whose only established use is the emergency reversal of dabigatran’s anticoagulant effect. The TxGNN model predicts a possible effect on Hemoglobinopathy, but this prediction is currently supported by 0 clinical trials and 0 publications, and the model’s own rationale flags the mechanistic link as implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Reversal of dabigatran (anticoagulant) activity in emergency/life-threatening bleeding — not present as structured license data in this dataset (Data Gap DG001); stated here from general drug knowledge only |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 95.66% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action documentation for Idarucizumab is not available in this dataset (Data Gap DG002). However, the model’s own repurposing rationale describes its only known pharmacological action: Idarucizumab binds free and thrombin-bound dabigatran molecules and neutralizes their anticoagulant activity. This is a highly specific, target-restricted mechanism with no known relationship to hemoglobin structure, globin gene function, or red-cell pathology.
Hemoglobinopathies (e.g., sickle cell disease, other hemoglobin structural variants) arise from globin gene mutations and abnormal hemoglobin polymerization — a disease process that has no described biochemical or pharmacological overlap with dabigatran neutralization. The evidence pack’s own analysis characterizes this prediction as a likely false-positive signal driven by knowledge-graph embedding similarity rather than a biologically grounded hypothesis.
This assessment is reinforced by a broader pattern in the prediction set: the next four highest-ranked candidates for this drug (rheumatoid arthritis, 16p13.3 deletion syndrome, beta-thalassemia, and pyruvate kinase deficiency) all score similarly high yet share the same absence of any supporting clinical trial or literature evidence, and each is flagged in the rationale as lacking a plausible mechanistic basis. Taken together, this suggests the model’s embedding neighborhood for Idarucizumab is poorly informed by real-world evidence at this time, rather than pointing to a genuine repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
No marketing authorisations are currently recorded for Idarucizumab in this dataset (market status: Not marketed, 0 licenses on file). Formal Summary of Product Characteristics (SmPC) data has not been retrieved for this candidate (Data Gap DG001).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (hemoglobinopathy) has no supporting clinical trials or literature, and the model’s own mechanistic rationale finds no plausible biological pathway connecting dabigatran-reversal activity to hemoglobinopathy pathology — this is most likely a knowledge-graph artifact rather than a genuine repurposing signal. In addition, safety documentation (warnings, contraindications, drug interactions) is a blocking data gap (DG001), which independently precludes any safety pre-assessment.
To proceed, the following is needed:
- Retrieval of the approved SmPC / product label (warnings, contraindications, DDI) to close the blocking data gap (DG001)
- Confirmed mechanism-of-action documentation from DrugBank or equivalent source (DG002)
- Independent biological or preclinical evidence linking Idarucizumab (or its Fab-fragment antibody class) to red-cell/hemoglobin pathology before any further evaluation is warranted
- Re-review of the TxGNN prediction set for this drug, given that all top-ranked candidates share the zero-evidence, low-plausibility pattern noted above
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.